Xaloplat 50 MG & 100 MG (Oxaliplatin)
Product Name : Xaloplat
Generic Name : Oxaliplatin
Formulation : Injection
Available Pack Size : 1’s
Available Strengths : 50 mg & 100 mg
Registrations : Bangladesh
Product Information
Xaloplat (Oxaliplatin) 50mg & 100mg is a platinum-based chemotherapy agent, administered by intravenous infusion under the supervision of a qualified oncology team, used for the treatment of colorectal cancer in combination with 5-fluorouracil and leucovorin (the FOLFOX regimen). It works by forming crosslinks within tumour cell DNA, blocking DNA replication and transcription and triggering cancer cell death. Manufactured for the Bangladesh market and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Xaloplat (Oxaliplatin) 50mg & 100mg
| Brand Name | Xaloplat (Oxaliplatin) |
| Generic Name | Oxaliplatin INN |
| Drug Class | Platinum-Based Antineoplastic Agent (Alkylating-Like Agent) |
| Available Strengths | 50mg and 100mg (5mg/mL concentration in each vial) |
| Formulation | Sterile Concentrate for Solution for Intravenous Infusion (Injection Vial) |
| Pack Size | 1’s (single vial per pack), available in 50mg and 100mg vial sizes. The number and strength of vials needed per infusion depends on the patient’s body surface area and prescribed dose. |
| Primary Indication | Colorectal Cancer, in combination with 5-Fluorouracil and Leucovorin (FOLFOX) |
| Regulatory Approvals | USFDA Approved (adjuvant Stage III colon cancer after resection; metastatic colorectal cancer, both with 5-FU/leucovorin). EMA Approved (colorectal cancer, with 5-FU/leucovorin). |
| Originator Brand | Eloxatin by Sanofi |
| Manufacturer | [Manufacturer name to be confirmed], Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Registered in Bangladesh |
| Storage Conditions | Store below 25 degrees Celsius, protected from light. Do not freeze. Once opened or diluted, use according to the pharmacy’s stability and handling protocol. |
How Xaloplat (Oxaliplatin) Works
Xaloplat contains Oxaliplatin, a third-generation platinum-based chemotherapy agent. Once inside the cell, Oxaliplatin forms platinum-DNA crosslinks, both within a single DNA strand and between the two strands of the double helix. These crosslinks distort the DNA structure and prevent the cell’s normal replication and transcription machinery from functioning correctly.
Because rapidly dividing cancer cells depend heavily on accurate DNA replication to multiply, this damage triggers cell cycle arrest and programmed cell death (apoptosis) in tumour cells. Oxaliplatin is used as part of combination chemotherapy, most commonly in the FOLFOX regimen alongside 5-fluorouracil and leucovorin, which act on cancer cells through complementary mechanisms.
Xaloplat is administered as an intravenous infusion, typically over about 2 hours, by trained oncology healthcare professionals in a hospital or chemotherapy infusion setting. It is not self-administered and is not intended for home use.
Indications for Xaloplat (Oxaliplatin)
Xaloplat (Oxaliplatin) is indicated for the following, always in combination with 5-fluorouracil and leucovorin:
|
Adjuvant Stage III Colon Cancer For adult patients with Stage III colon cancer, given after complete surgical resection of the primary tumour, to reduce the risk of recurrence. |
Metastatic Colorectal Cancer For adult patients with metastatic colorectal cancer, as first-line or subsequent-line treatment, per the treating oncologist’s protocol. |
Oxaliplatin-based regimens are also used off-label in several other gastrointestinal and solid tumour types according to clinical guidelines and institutional protocols; the specific regimen and combination partners should always be confirmed against current prescribing information and the treating oncologist’s plan.
Benefits of Xaloplat (Oxaliplatin)
|
Established Backbone of Colorectal Chemotherapy A core component of the widely used FOLFOX regimen, one of the most established chemotherapy combinations in colorectal cancer. |
Proven Adjuvant and Metastatic Use Approved both to help prevent recurrence after surgery for Stage III colon cancer and to treat metastatic disease. |
Two Vial Sizes for Flexible Dosing Available as 50mg and 100mg vials, allowing hospital pharmacies to prepare individualised, body-surface-area-based doses with less product wastage. |
|
Affordable Alternative to Eloxatin Xaloplat contains the same active ingredient as Eloxatin by Sanofi, at a significantly lower cost, improving access for cancer centres and patients. |
Complementary Mechanism Works through DNA crosslinking, a mechanism distinct from and complementary to 5-fluorouracil, supporting combination regimen efficacy. |
WHO-GMP and cGMP Certified Manufactured under strict WHO-GMP, cGMP, and ISO-certified standards, ensuring every batch of Xaloplat meets consistent quality and safety requirements. |
Administration of Xaloplat (Oxaliplatin)
Route: Intravenous (IV) infusion only, typically over approximately 2 hours (may be extended for tolerability), following dilution per the treating institution’s pharmacy protocol.
Who administers it: Must be prepared and administered by trained oncology healthcare professionals in a hospital or chemotherapy infusion setting. Not for self-administration or home use.
Typical dosing: Dosed by body surface area (mg/m²) as part of a specific FOLFOX protocol, given every 2 weeks alongside 5-fluorouracil and leucovorin. The exact dose, schedule, and total number of cycles is determined by the treating oncologist based on the indication (adjuvant or metastatic) and patient tolerability.
Equipment requirement: Aluminium-containing needles or intravenous administration sets must never be used for preparing or giving Xaloplat, as aluminium causes degradation of the active substance. Only aluminium-free equipment should be used throughout preparation and administration.
Cold sensitivity precautions: Patients are typically advised to avoid cold drinks, ice, and exposure to cold air or objects for several days after each infusion, as cold can trigger or worsen acute nerve-related symptoms.
Renal impairment: Dose adjustment is generally required in patients with reduced kidney function; the treating oncologist will determine the appropriate dose based on renal status.
Monitoring and Key Toxicities
The signature toxicity of Xaloplat is peripheral sensory neuropathy, which occurs in two distinct forms: an acute, transient, cold-triggered pattern that appears during or shortly after infusion (numbness, tingling, jaw tightness, or throat discomfort with swallowing or breathing, which is usually not true bronchospasm but can feel alarming), and a chronic, cumulative pattern that can persist for months or years and is dose-limiting at higher cumulative doses. Patients should report new or worsening numbness, tingling, or throat/jaw discomfort promptly.
Regular monitoring includes complete blood counts for neutropenia, thrombocytopenia, and anaemia, liver function tests, and watchfulness for hypersensitivity reactions (rash, itching, swelling, or, rarely, bronchospasm or a drop in blood pressure), which can occur at any cycle and may become more likely with repeated exposure. The infusion site should be monitored closely for signs of leakage into surrounding tissue. Report any unexplained cough, breathlessness, fever, unusual bleeding, or infusion site pain, redness, or swelling to the care team immediately.
Drug Interactions and Important Information
As a platinum-based cytotoxic agent, Xaloplat does not undergo significant cytochrome P450 metabolism, so classic small-molecule drug interactions are limited. However, caution is advised with other nephrotoxic or ototoxic medications, and with other agents that can independently cause peripheral neuropathy or myelosuppression, as combined effects may be additive. Live vaccines should be avoided during and shortly after treatment, given the effect on the immune system.
As above, aluminium-containing equipment must never be used in preparation or administration, as this is a chemical degradation issue rather than a patient drug interaction. Always ensure the full combination regimen (5-fluorouracil, leucovorin, and any other concurrent medications) is reviewed by the treating oncology team before each cycle.
Side Effects and Precautions
|
Common Side Effects Peripheral sensory neuropathy (numbness, tingling) Nausea and vomiting Diarrhoea Fatigue Reduced blood counts (neutropenia, thrombocytopenia, anaemia) Fever and injection site reactions |
Serious Warnings and Precautions Severe or cumulative peripheral neuropathy, which can be dose-limiting and long-lasting. Hypersensitivity reactions, including rare anaphylaxis, bronchospasm, or hypotension. Severe myelosuppression, increasing infection and bleeding risk. Hepatotoxicity, including sinusoidal obstruction syndrome (liver injury). Rare interstitial lung disease/pulmonary fibrosis, including fatal cases. Not recommended during pregnancy; embryo-fetal toxicity. |
Who Should Use Xaloplat (Oxaliplatin)?
Xaloplat is intended for adult patients with Stage III colon cancer receiving adjuvant chemotherapy after surgical resection, or adult patients with metastatic colorectal cancer, always given in combination with 5-fluorouracil and leucovorin. It is administered exclusively in a hospital or specialist oncology infusion setting by trained healthcare professionals equipped to manage hypersensitivity and infusion-related complications. Baseline blood counts, liver and kidney function, and a neurological assessment should be completed before starting treatment.
Manufacturer
Xaloplat (Oxaliplatin) is manufactured in Bangladesh under strict WHO-GMP, cGMP, and ISO-certified standards, offering an affordable and bioequivalent alternative to Eloxatin by Sanofi at a fraction of the cost. [Please confirm the exact manufacturer name so it can be added here and in the specs table above.]
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty oncology medications. We ensure Xaloplat (Oxaliplatin) is accessible to hospitals and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Xaloplat (Oxaliplatin) from Mediaid Pharmacy?
Xaloplat represents a foundational chemotherapy option for hospitals and cancer centres treating colorectal cancer. As the generic equivalent of Eloxatin by Sanofi, it delivers the same active ingredient, Oxaliplatin, with the same proven platinum-based mechanism at a dramatically more affordable price. Manufactured under WHO-GMP and cGMP standards and distributed globally by Mediaid Pharmacy, Xaloplat gives cancer centres worldwide access to high-quality chemotherapy without the financial burden of brand-name alternatives. For institutions seeking a proven, affordable, and accessible Oxaliplatin option with worldwide delivery, Xaloplat from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Xaloplat (Oxaliplatin)
What is Xaloplat (Oxaliplatin) used for?
Xaloplat (Oxaliplatin) is a platinum-based chemotherapy agent used to treat colorectal cancer, both as adjuvant treatment after surgery for Stage III colon cancer and for metastatic disease. It is always given in combination with 5-fluorouracil and leucovorin, in a regimen commonly known as FOLFOX, and works by damaging cancer cell DNA to stop tumour growth.
How is Xaloplat (Oxaliplatin) given?
Xaloplat is given as an intravenous infusion, usually over about 2 hours, in a hospital or chemotherapy infusion centre by trained oncology staff. It is never self-administered at home. The dose is calculated based on body surface area as part of a specific FOLFOX protocol, typically repeated every 2 weeks.
What strength and pack size is Xaloplat available in?
Xaloplat is supplied as single-use vials in two sizes, 50mg and 100mg (5mg/mL concentration), packed as 1’s (one vial per pack). The hospital pharmacy selects and combines vial sizes to prepare the exact dose calculated for each patient.
Is Xaloplat the same as Eloxatin (Oxaliplatin by Sanofi)?
Yes. Xaloplat is the generic equivalent of Eloxatin. Both contain the same active ingredient, Oxaliplatin, in the same concentration and vial sizes. Xaloplat delivers the same clinical benefits as Eloxatin at a significantly lower cost, making it a more accessible option for cancer centres worldwide.
What are the side effects of Xaloplat (Oxaliplatin)?
The most characteristic side effect is peripheral nerve sensitivity, including a distinctive cold-triggered pattern of numbness, tingling, or throat/jaw discomfort during or shortly after infusion, as well as a longer-lasting cumulative neuropathy. Other common effects include nausea, diarrhoea, fatigue, and reduced blood counts. Serious but less common risks include hypersensitivity reactions, severe myelosuppression, and liver toxicity. Always consult the treating oncologist for a complete assessment of individual risks and benefits.
Why can’t aluminium equipment be used with Xaloplat?
Aluminium reacts with and degrades Oxaliplatin, reducing the effectiveness of the dose. For this reason, only aluminium-free needles, syringes, and IV administration equipment should be used when preparing and giving Xaloplat, in line with standard chemotherapy handling protocols.
Can hospitals order Xaloplat (Oxaliplatin) with worldwide shipping?
Yes. Mediaid Pharmacy supplies Xaloplat (Oxaliplatin) 50mg and 100mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Xaloplat (Oxaliplatin) 50mg & 100mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
